Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms

Thyroid

Volumn 18, Issue 10, 2008, Pages 1055-1063

  Wang, Yongchun ^a   Kowalski, Jeanne ^a   Tsai, Hua Ling ^a   Marik, Radharani ^a   Prasad, Nijaguna ^a   Somervell, Helina ^a   Lo, Pang Kuo ^a   Sangenario, Lauren E ^a   Dyrskjot, Lars ^b   Orntoft, Torben F ^b   Westra, William H ^a   Meeker, Alan K ^a   Eshleman, James R ^a   Umbricht, Christopher B ^a   Zeiger, Martha A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; ARTICLE; ASPIRATION BIOPSY; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTIC THYROIDITIS; NUCLEOTIDE SEQUENCE; ONCOCYTOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID ADENOMA; THYROID CANCER; THYROID CARCINOMA; THYROID NODULE; THYROID TUMOR;

ADENOMA; ADENOMA, OXYPHILIC; ALTERNATIVE SPLICING; CARCINOMA, PAPILLARY, FOLLICULAR; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TELOMERASE; THYROID NEOPLASMS;

EID: 53649101072     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0101     Document Type: Article

References (42)

1. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK 2002 Diagnosis of follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 26:41-44.
2. Yoder BJ, Redman R, Massoll NA 2006 Validation of a five-tier cytodiagnostic system for thyroid fine needle aspiration biopsies using cytohistologic correlation. Thyroid 16:781-786.
3. Hayat MJ, Howlader N, Reichman ME, Edwards BK 2007 Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12:20-37.
4. Gharib H, Papini E 2007 Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am 36:707-735.
5. Chen H, Zeiger MA, Clark DP, Westra WH, Udelsman R 1997 Papillary thyroid cancer: can operative management be solely based on fine needle aspiration? J Am Coll Surg 184:605-610.
6. Carling T, Udelsman R 2005 Follicular neoplasms of the thyroid: what to recommend. Thyroid 15:583-587.
7. Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL 2001 Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg 233:716-722.
8. Mechanick JI, Carpi A 2006 Progress in the preoperative diagnosis of thyroid nodules: managing uncertainties and the ultimate role for molecular investigation. Biomed Pharmacother 60:396-404.
9. Cheng AJ, Lin JD, Chang T, Wang TC 1998 Telomerase activity in benign and malignant human thyroid tissues. Br J Cancer 77:2177-2180.
10. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S 1997 Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 57:2144-2147.
11. Saji M, Westra WH, Chen H, Umbricht CB, Tuttle RM, Box MF, Udelsman R, Sukumar S, Zeiger MA 1997 Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid. Surgery 122:1137-1140.
12. Saji M, Xydas S, Westra WH, Liang CK, Clark DP, Udelsman R, Umbricht CB, Sukumar S, Zeiger MA 1999 Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 5:1483-1489.
13. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A 2005 Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer Res 25:509-514.
14. Kalnina Z, Zayakin P, Silina K, Line A 2005 Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42:342-357.
15. Skotheim RI, Nees M 2007 Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 39:1432-1449.
16. Brinkman BM 2004 Splice variants as cancer biomarkers. Clin Biochem 37:584-594.
17. Venables JP 2004 Aberrant and alternative splicing in cancer. Cancer Res 64:7647-7654.
18. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA 1997 Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6:2011-2019.
19. Hisatomi H, Ohyashiki K, Ohyashiki JH, Nagao K, Kanamaru T, Hirata H, Hibi N, Tsukada Y 2003 Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. Neoplasia 5:193-197.
20. Wick M, Zubov D, Hagen G 1999 Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232:97-106.
21. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR 2000 The hTERT alpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2:426-432.
22. Fan Y, Liu Z, Fang X, Ge Z, Ge N, Jia Y, Sun P, Lou F, Bjorkholm M, Gruber A, Ekman P, Xu D 2005 Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res 11:4331-4337.
23. Ulaner GA, Hu J-F, Vu TH, Ciudice LC, Hoffman AR 1998 Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58:4168-4172.
24. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, Hoffman AR 2000 Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 85:330-335.
25. Yokoyama Y, Wan X, Takahashi Y, Shinohara A, Tamaya T 2001 Alternatively spliced variant deleting exons 7 and 8 of the human telomerase reverse transcriptase gene is dominantly expressed in the uterus. Mol Hum Reprod 7:853-857.
26. Zaffaroni N, Della Porta C, Villa R, Botti C, Buglioni S, Mottolese M, Grazia Daidone M 2002 Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. J Pathol 198:37-46.
27. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, DePinho RA 1999 Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18:1219-1226.
28. Brambilla C, Folini M, Gandellini P, Daprai L, Daidone MG, Zaffaroni N 2004 Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cell Mol Life Sci 61:1764-1774.
29. DeLong ER, DeLong DM, Clarke-Pearson DL 1988 Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837-845.
30. Gallop RJ, Crits-Christoph P, Muenz LR, Tu XM 2003 Determination and interpretation of the optimal operating point for ROC curves derived through generalized linear models. Understanding Stat 2:219-242.
31. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R 1999 Direct activation of TERT transcription by c-MYC. Nat Genet 21:220-224.
32. Umbricht CB, Conrad GT, Clark DP, Westra WH, Smith DC, Zahurak M, Saji M, Smallridge RC, Goodman S, Zeiger MA 2004 Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors. Clin Cancer Res 10:5762-5768.
33. Mora J, Lerma E 2004 Telomerase activity in thyroid fine needle aspirates. Acta Cytol 48:818-824.
34. Liou MJ, Chan EC, Lin JD, Liu FH, Chao TC 2003 Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett 191:223-227.
35. Haff LA 1994 Improved quantitative PCR using nested primers. PCR Methods Appl 3:332-337.
36. Takahashi T, Tamura M, Takahashi SN, Matsumoto K, Sawada S, Yokoyama E, Nakayama T, Mizutani T, Takasu T, Nagase H 2007 Quantitative nested real-time PCR assay for assessing the clinical course of tuberculous meningitis. J Neurol Sci 255:69-76.
37. Zeiger MA, Dackiw AP 2005 Follicular thyroid lesions, elements that affect both diagnosis and prognosis. J Surg Oncol 89:108-113.
38. Renshaw AA, Gould EW 2002 Why there is the tendency to "overdiagnose" the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 117:19-21.
39. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME 2004 Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336-1340.
40. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES 1999 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537.
41. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, Nakayama J, Ishikawa F, Ide T 1999 Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18:1561-1567.
42. Nakamura Y, Tahara E, Tahara H, Yasui W, Ide T 1999 Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues. Mol Carcinog 26:312-320.